Details for New Drug Application (NDA): 021493
✉ Email this page to a colleague
The generic ingredient in ZYMAR is gatifloxacin. There are sixteen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the gatifloxacin profile page.
Summary for 021493
Tradename: | ZYMAR |
Applicant: | Allergan |
Ingredient: | gatifloxacin |
Patents: | 0 |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION/DROPS;OPHTHALMIC | Strength | 0.3% | ||||
Approval Date: | Mar 28, 2003 | TE: | RLD: | Yes |
Expired US Patents for NDA 021493
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Allergan | ZYMAR | gatifloxacin | SOLUTION/DROPS;OPHTHALMIC | 021493-001 | Mar 28, 2003 | 4,980,470*PED | ⤷ Subscribe |
Allergan | ZYMAR | gatifloxacin | SOLUTION/DROPS;OPHTHALMIC | 021493-001 | Mar 28, 2003 | 6,333,045*PED | ⤷ Subscribe |
Allergan | ZYMAR | gatifloxacin | SOLUTION/DROPS;OPHTHALMIC | 021493-001 | Mar 28, 2003 | 5,880,283*PED | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription